HUTCHMED (China) Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HUTCHMED (China) Limited
Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m.
The China-based biopharma company is seeking up to $602.8m gross in its Hong Kong IPO.
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.
Keeping Track: First COVID Vaccine BLA Kicks Off; Oncology Submissions From Hutchmed, Takeda And Shorla
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- OTC, Consumer
- Other Names / Subsidiaries
- Hutchison Whampoa
- Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited
- Hutchison China MediTech Limited